Eat This, Not That! “According to a study performed by UCI MIND and presented at the American Association for the Advancement of Science, there’s a connection between longevity and drinking a moderate amount of alcohol. (Let’s stress …
Read More
News
When the U.S. Food and Drug Administration gave controversial accelerated approval to the first Alzheimer’s drug in nearly 20 years, it had a surprising impact on attitudes about research into the disease. A survey by University of California, Irvine neuroscientists has found news coverage of the FDA’s decision made the public less willing to volunteer for Alzheimer’s pharmaceutical trials. The study was conducted by the UCI Institute for Memory Impairments and Neurological Disorders, known as UCI MIND. It appears in the Journal of Alzheimer’s Disease. (Link to abstract) The UCI team performed the survey in tandem with the FDA’s spring…
The post Controversial Alzheimer’s drug approval sparks surprising impact appeared first on UCI MIND.
Contributed by Joshua Grill, PhD On the opening night of the Clinical Trials for Alzheimer’s Disease (CTAD) meeting, a packed room was abuzz with excitement. The evening included five presentations related to the Phase 3 CLARITY-AD trial of lecanemab, a monoclonal antibody against the beta amyloid protein that builds up in the brain of a person with Alzheimer’s disease. The excitement and anticipation were palpable, since the sponsor of the trial, Eisai, had announced in September that the results were positive. The presentations were accompanied by the full publication of the results in the New England Journal of Medicine and coverage…
The post CTAD Abuzz appeared first on UCI MIND.
Contributed by Joshua Grill, PhD and David Sultzer, MD An article in ScienceInsider, a news outlet published by Science magazine, reports on an unpublished case of a person who died after treatment with the monoclonal antibody lecanemab. Lecanemab is a promising investigational treatment, seemingly poised for FDA approval as a disease-modifying treatment for Alzheimer’s disease. Topline results were announced in September that indicated lecanemab had been shown to slow progression of disease. The full data will be presented tomorrow at the Clinical Trials in Alzheimer’s Disease (CTAD) international conference. The presentation should include efficacy as well as safety data for lecanemab. As…
The post Are there new safety concerns for Lecanemab? appeared first on UCI MIND.
Irvine, Calif. – UCI Health and UCI Alpha Clinic have launched the first U.S. clinical trial to test the safety and tolerability of IMM01-STEM in patients with knee osteoarthritis to prevent muscle atrophy.
Up to 18 patients ranging in age from …
Irvine, Calif. – UCI Health and UCI Alpha Clinic have launched the first and only U.S. clinical trial to test the safety and tolerability of IMM01-STEM in patients with muscle atrophy related to knee osteoarthritis.
Up to 18 patients ranging in …
The actor Chris Hemsworth recently publicly disclosed that he learned that he carries two copies of the Alzheimer’s disease risk gene Apolipoprotein (APOE) e4 (https://www.goodmorningamerica.com/culture/story/chris-hemsworth-discovers-risk-alzheimers-disease-series-limitless-93442609). We’ve previously discussed direct-to-consumer genetic testing that includes the option for APOE testing on the UCI MIND blog (https://mind.uci.edu/fda-approves-23andme-limited-direct-consumer-genetic-risk-testing/). APOE is the strongest known genetic risk factor for Alzheimer’s disease. People who carry one or two copies of the e4 allele are at increased risk for Alzheimer’s disease, while people who carry the e2 allele are at lower risk (most people carry two copies of the e3 allele). But people with e4 don’t always develop…
The post Learning Alzheimer’s Risk appeared first on UCI MIND.
Healthline – “There is a lot of evidence that links sleep apnea to Alzheimer’s disease risk,” added Bryce Mander, Ph.D, assistant professor, Psychiatry & Human Behavior, School of Medicine at the University of California, Irvine. “But there i…
UCI MIND Director Joshua Grill, PhD and Jason Karlawish, PhD, Co-Director of the Penn Memory Center were featured in a recent podcast episode for the Wisconsin Alzheimer’s Disease Research Center: The Case for Disclosing Biomarker Results to Al…
Orange, Calif., – UCI Health received its 17th consecutive ‘A’ in the fall 2022 Leapfrog Hospital Safety Grade. This national distinction, which recognizes a health system’s commitment to patient safety and achievements in preventing harm, …
Orange, Calif., – UCI Health received its 17th consecutive “A” in the fall 2022 Leapfrog Hospital Safety Grade. This national distinction, which recognizes a health system’s commitment to patient safety and achievements in preve…
Contributed by Joshua Grill, PhD On November 14, Roche announced negative topline results for their GRADUATE program testing gantenerumab, a monoclonal antibody against the beta amyloid protein that accumulates in the brain of people with Alzheimer’s disease. The program included two phase 3 trials (GRADUATE 1 and GRADUATE 2). As with other recent trials, the studies included patients with “early Alzheimer’s disease,” including people with Mild Cognitive Impairment and mild dementia. The trials were large and lengthy, with 1965 participants (across the two studies) who were followed for 27 months. According to the press release, participants randomized to gantenerumab demonstrated…
The post Topline results announced for Phase 3 trial of gantenerumab appeared first on UCI MIND.
Orange, Calif. — UCI Health and General Catalyst have formed a multiyear collaboration to advance digital transformation that increases the efficiency of healthcare delivery, expands health equity and creates new care models that meet the changin…
Orange, Calif. — UCI Health and General Catalyst have formed a multiyear collaboration to advance digital transformation that increases the efficiency of healthcare delivery, expands health equity and creates new care models that meet the changin…
Irvine, Calif. — More than 3,000 participants, donors and supporters who joined the 2022 UCI Anti-Cancer Challenge on Oct. 8 helped raise $1 million for innovative cancer research.
All proceeds will support promising cancer pilot projects and ear…
Irvine, Calif. — More than 3,000 participants, donors and supporters who joined the 2022 UCI Anti-Cancer Challenge on Oct. 8 helped raise $1 million for innovative cancer research.
All proceeds will support promising cancer pilot projects and ear…
Find out in this infographic from the National Institute on Aging: https://go.usa.gov/xtEmu
The post If a family member has Alzheimer’s disease, will I have it, too? appeared first on UCI MIND.
“Researchers are working hard to find a cure to Alzheimer’s disease … Through their efforts, new research and studies have proven helpful in ways to prevent the disease and even possible treatments. We learn about these findings from our pa…
Irvine, Calif. — UCI Health and the UCI Alpha Clinic are conducting a clinical trial of an investigational cell therapy in patients with generalized myasthenia gravis, a rare autoimmune disorder.
The therapy, called Descartes-08, is an mRNA-modif…
Irvine, Calif. — UCI Health and the UCI Alpha Clinic are conducting a clinical trial of an investigational cell therapy in patients with generalized myasthenia gravis, a rare autoimmune disorder.
The therapy, called Descartes-08, is an mRNA-modif…